SCIENCE

IgE-related allergic diseases such as atopic dermatitis, allergic asthma, hyper-IgE syndrome , and food allergies

Treats and prevents allergic diseases by inhibiting the B lymphocytes, which express IgE

1. Completed a phase 1 clinical trial in the US
2. Completed a phase 2a clinical trial atopic dermatitis  in the US
3. A phase 2a clinical trial in allergic asthma in Taiwan is ongoing
    

1. Uniqueness: Has a novel drug target and mechanism by inhibiting the source of IgE, i.e., the IgE B cells.
2. Safety: Has a specific pharmacological mechanism and limited side effects.
3. Extensive use: Has a wide range of indications and is applicable to more allergy and asthma patients than its existing counterparts.
4. Economy: FB825 has excellent pharmacokinetic properties with a long half-life. An administration frequency of once every 2-3 months is anticipated. The long-acting advantage provides great convenience to patients and helps reduce medical costs.

According to analysis reports by Allied Market Research and Coherent Market Insights, the global market size of atopic dermatitis/asthma treatment will reach USD 38 billion in 2027.